Skip to main content

Table 1 Details of the control and patient-specific pluripotent stem cell lines used for drug testing

From: Effects of cardioactive drugs on human induced pluripotent stem cell derived long QT syndrome cardiomyocytes

Cell line Line type Mutation Disease Affected current Source Purpose
H7 (hESC) hESC Wild type None None ICM hESC control
UTA.00112.hFF (WTa) hiPSC Wild type None None hFF Control
UTA.01006.WT (WTb) hiPSC Wild type None None hADF Adult control
UTA.00208.LQT1θ,*,s hiPSC G589D LQT1 IKs hADF Symptomatic, patient-specific
UTA.00211.LQT1θ,*,s hiPSC G589D LQT1 IKs hADF Symptomatic, patient-specific
UTA.00303.LQT1ψ,*,a hiPSC G589D LQT1 IKs hADF Asymptomatic mutation carrier-specific
UTA.00313.LQT1ψ,*,a hiPSC G589D LQT1 IKs hADF Asymptomatic mutation carrier-specific
UTA.00514.LQT2‡,a hiPSC R176W LQT2 IKr hADF Asymptomatic mutation carrier-specific
UTA.00525.LQT2‡,a hiPSC R176W LQT2 IKr hADF Asymptomatic mutation carrier-specific
  1. ICM inner cell mass of blastocyst, hFF human foreskin fibroblast, hADF human adult dermal fibroblast, hESC human embryonic stem cell, hiPSC human induced pluripotent stem cell
  2. * Siblings ‡, θ, ψ clonal lines from same individual s symptomatic a asymptomatic